The Clorox Company (NYSE:CLX) Receives $158.21 Average Target Price from Analysts

Shares of The Clorox Company (NYSE:CLX) have earned a consensus recommendation of “Reduce” from the fifteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $158.21.

Several brokerages recently commented on CLX. Wells Fargo & Company boosted their price target on Clorox from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 4th. Barclays boosted their price target on Clorox from $130.00 to $140.00 and gave the company an “underweight” rating in a research note on Wednesday, February 5th. Evercore ISI boosted their price target on Clorox from $145.00 to $155.00 in a research note on Tuesday, February 4th. Royal Bank of Canada reissued a “sector perform” rating and issued a $150.00 price target on shares of Clorox in a research note on Thursday, January 30th. Finally, DA Davidson lowered their price target on Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. American Trust acquired a new position in shares of Clorox in the fourth quarter valued at $293,000. Putney Financial Group LLC acquired a new position in Clorox during the fourth quarter worth $104,000. AlphaCore Capital LLC acquired a new position in Clorox during the fourth quarter worth $694,000. Mackenzie Financial Corp raised its stake in Clorox by 30.5% during the fourth quarter. Mackenzie Financial Corp now owns 13,464 shares of the company’s stock worth $2,187,000 after acquiring an additional 3,148 shares in the last quarter. Finally, Ball & Co Wealth Management Inc. acquired a new position in Clorox during the fourth quarter worth $139,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Price Performance

Shares of CLX opened at $157.41 on Friday. The company has a market capitalization of $19.39 billion, a price-to-earnings ratio of 43.01, a P/E/G ratio of 2.62 and a beta of 0.42. Clorox has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The business’s 50-day moving average is $157.72 and its 200-day moving average is $159.96.

Clorox (NYSE:CLX) last issued its earnings results on Monday, February 3rd. The company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.16. Clorox had a return on equity of 316.87% and a net margin of 6.38%. During the same period in the prior year, the business posted $2.16 EPS. Equities research analysts expect that Clorox will post 7.15 EPS for the current fiscal year.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.